Related Experiment Video
Updated: Sep 11, 2026

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons
Published on: April 3, 2014
A Series of Aryl-Substituted-(biphenyl)methyl-sulfinylmethylthiazoles as Novel and Atypical Dopamine Transporter
Gisela A Camacho-Hernandez1,2, Jianjing Cao1, Amarachi Okorom1
1Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse─Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland21224, United States.
Abstract:
Dependence on psychostimulants, including cocaine and methamphetamine, is driving the fourth wave of U.S. drug overdoses. The search for atypical dopamine transporter (DAT) inhibitors for the treatment of psychostimulant use disorders has identified both structurally and pharmacologically diverse compounds that bind DAT but do not produce cocaine-like behaviors in experimental animals. Nevertheless, low binding affinity at hDAT, metabolic instability and high potency in the human ether-à-go-go-related gene (hERG) channel have limited further development. Herein, we describe the synthesis of a novel series of aryl-substituted-(biphenyl)methyl-sulfinylmethylthiazoles and identify two lead molecules, 32b and 39b that bind hDAT (Ki = 63.0 and 78.5 nM, respectively) and have hERG channel activities predicted to be in the low μM range. Despite demonstrated brain penetrability and target engagement neither compound produced cocaine-like locomotor stimulation or conditioned place preference, in mice, thus representing a new class of atypical DAT inhibitors and potential leads for pharmacotherapeutic development.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Antihypertensive Drugs: Thiazide-Class Diuretics
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Synthesis
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists